IC
IMUX icon

Ikarian Capital’s Immunic IMUX Stock Holding History

Ikarian Capital’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,150
Closed -$213K – 133
2022
Q2 		$213K Hold
6,150
– – 0.04% 119
2022
Q1 		$696K Buy
+6,150
New +$712K 0.09% 113

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ikarian Capital's IMUX Position: Q1 2026 in Review

Ikarian Capital held its Immunic (IMUX) position steady in Q1 2026 at 67,466 shares worth $749K. The position accounts for 0.06% of the portfolio, ranked #116.

Ikarian Capital first reported a position in IMUX in Q2 2022 and has held it in 14 quarters since. The position peaked at $2.13M in Q1 2024. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Ikarian Capital held 67,466 shares of Immunic worth $749K as of Q1 2026.
  • Ikarian Capital left its Immunic share count unchanged in Q1 2026.
  • Immunic made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #116 holding.
  • Ikarian Capital first reported a position in Immunic in Q2 2022 and has held it in 14 quarters since.
  • Ikarian Capital's Immunic position peaked at $2.13M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.